Clinical Trial

An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy

Study acronym: ENDURE
Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
This is a multicenter, prospective, observational Phase 4 study including a post marketing safety requirement, designed to collect both medical history data and prospective data on Duchenne muscular dystrophy (DMD) treatment outcomes in participants receiving delandistrogene moxeparvovec (ELEVIDYS) as part of clinical care, compared to participants with DMD receiving or prescribed to start chronic glucocorticoid treatment at the time of study enrollment in routine clinical practice.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2024-02-13; most recent amendment 2026-04-28.
Status change: Recruiting → Enrolling by Invitation 2025-08-08
Status change: Not Yet Recruiting → Recruiting 2024-03-08
Trial Details
NCT Number NCT06270719
Lead Sponsor Sarepta Therapeutics, Inc.
Conditions Duchenne Muscular Dystrophy
Enrollment 500 participants
Start Date 2024-02-07
Primary Completion 2029-12-31 (estimated)
Study Completion 2038-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-04